HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, has announced that it intends to offer and sell shares of its common stock and shares of its non-voting Series A convertible preferred stock in an underwritten public offering (the “Offering”).
HOOKIPA said that it also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the Offering, including the shares of common stock underlying the non-voting Series A convertible preferred stock.
SVB Leerink and RBC Capital Markets are acting as joint book-running managers of the Offering, the company said.